Lotus Pharmaceutical Co., Ltd. (1795.TW)
TWD 220.5
(-3.08%)
TWD 220.5
(-3.08%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 15.65 Billion TWD | -0.0% |
| 2022 | 15.65 Billion TWD | 54.22% |
| 2021 | 10.15 Billion TWD | -7.76% |
| 2020 | 11 Billion TWD | 8.2% |
| 2019 | 10.17 Billion TWD | 41.84% |
| 2018 | 7.17 Billion TWD | -9.91% |
| 2017 | 7.96 Billion TWD | 15.68% |
| 2016 | 6.88 Billion TWD | 1.65% |
| 2015 | 6.77 Billion TWD | -9.22% |
| 2014 | 7.45 Billion TWD | 1354.11% |
| 2013 | 512.97 Million TWD | 14.56% |
| 2012 | 447.78 Million TWD | -14.66% |
| 2011 | 524.73 Million TWD | 6.27% |
| 2010 | 493.75 Million TWD | 97.35% |
| 2009 | 250.18 Million TWD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 16.15 Billion TWD | -5.69% |
| 2024 Q1 | 17.13 Billion TWD | 9.42% |
| 2023 Q2 | 16.25 Billion TWD | -1.89% |
| 2023 FY | 15.65 Billion TWD | -0.0% |
| 2023 Q1 | 16.56 Billion TWD | 5.81% |
| 2023 Q3 | 16.16 Billion TWD | -0.56% |
| 2023 Q4 | 15.65 Billion TWD | -3.13% |
| 2022 Q4 | 15.65 Billion TWD | 16.55% |
| 2022 Q3 | 13.43 Billion TWD | 10.16% |
| 2022 Q2 | 12.19 Billion TWD | -1.46% |
| 2022 FY | 15.65 Billion TWD | 54.22% |
| 2022 Q1 | 12.37 Billion TWD | 21.89% |
| 2021 Q3 | 10.11 Billion TWD | -6.74% |
| 2021 Q1 | 11.56 Billion TWD | 5.09% |
| 2021 FY | 10.15 Billion TWD | -7.76% |
| 2021 Q2 | 10.84 Billion TWD | -6.28% |
| 2021 Q4 | 10.15 Billion TWD | 0.42% |
| 2020 Q2 | 10.2 Billion TWD | -7.49% |
| 2020 Q1 | 11.02 Billion TWD | 8.4% |
| 2020 FY | 11 Billion TWD | 8.2% |
| 2020 Q4 | 11 Billion TWD | 6.23% |
| 2020 Q3 | 10.36 Billion TWD | 1.57% |
| 2019 FY | 10.17 Billion TWD | 41.84% |
| 2019 Q4 | 10.17 Billion TWD | -2.11% |
| 2019 Q3 | 10.39 Billion TWD | -3.34% |
| 2019 Q1 | 10.13 Billion TWD | 41.23% |
| 2019 Q2 | 10.75 Billion TWD | 6.15% |
| 2018 Q2 | 8.08 Billion TWD | 3.52% |
| 2018 Q3 | 8.02 Billion TWD | -0.8% |
| 2018 FY | 7.17 Billion TWD | -9.91% |
| 2018 Q1 | 7.8 Billion TWD | -1.91% |
| 2018 Q4 | 7.17 Billion TWD | -10.57% |
| 2017 Q3 | 7.76 Billion TWD | 0.09% |
| 2017 Q4 | 7.96 Billion TWD | 2.57% |
| 2017 FY | 7.96 Billion TWD | 15.68% |
| 2017 Q1 | 7.32 Billion TWD | 6.37% |
| 2017 Q2 | 7.75 Billion TWD | 5.93% |
| 2016 Q4 | 6.88 Billion TWD | -6.46% |
| 2016 FY | 6.88 Billion TWD | 1.65% |
| 2016 Q3 | 7.35 Billion TWD | 3.13% |
| 2016 Q2 | 7.13 Billion TWD | 5.62% |
| 2016 Q1 | 6.75 Billion TWD | -0.23% |
| 2015 Q1 | 7.22 Billion TWD | -3.08% |
| 2015 Q2 | 6.82 Billion TWD | -5.61% |
| 2015 Q3 | 6.83 Billion TWD | 0.21% |
| 2015 Q4 | 6.77 Billion TWD | -0.98% |
| 2015 FY | 6.77 Billion TWD | -9.22% |
| 2014 Q1 | 518.41 Million TWD | 1.06% |
| 2014 Q3 | 1.56 Billion TWD | 174.6% |
| 2014 Q2 | 568.85 Million TWD | 9.73% |
| 2014 FY | 7.45 Billion TWD | 1354.11% |
| 2014 Q4 | 7.45 Billion TWD | 377.52% |
| 2013 Q2 | 460.81 Million TWD | 3.63% |
| 2013 Q3 | 534.14 Million TWD | 15.91% |
| 2013 Q4 | 512.97 Million TWD | -3.96% |
| 2013 FY | 512.97 Million TWD | 14.56% |
| 2013 Q1 | 444.68 Million TWD | -0.69% |
| 2012 FY | 447.78 Million TWD | -14.66% |
| 2012 Q1 | 769.27 Million TWD | 46.6% |
| 2012 Q2 | 815.51 Million TWD | 6.01% |
| 2012 Q3 | 667.9 Million TWD | -18.1% |
| 2012 Q4 | 447.78 Million TWD | -32.96% |
| 2011 Q2 | 515.44 Million TWD | 2.79% |
| 2011 Q1 | 501.47 Million TWD | 1.56% |
| 2011 FY | 524.73 Million TWD | 6.27% |
| 2011 Q4 | 524.73 Million TWD | -2.2% |
| 2011 Q3 | 536.53 Million TWD | 4.09% |
| 2010 Q4 | 493.75 Million TWD | 0.0% |
| 2010 FY | 493.75 Million TWD | 97.35% |
| 2009 FY | 250.18 Million TWD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Grape King Bio Ltd | 3.88 Billion TWD | -303.357% |
| Standard Chem & Pharm CO., LTD. | 3.05 Billion TWD | -413.142% |
| Maywufa Company Ltd. | 794.91 Million TWD | -1869.765% |
| ScinoPharm Taiwan, Ltd. | 1.35 Billion TWD | -1053.733% |
| LIWANLI Innovation Co., Ltd. | 50.66 Million TWD | -30807.923% |
| YungShin Global Holding Corporation | 3.59 Billion TWD | -335.249% |
| PhytoHealth Corporation | 79.84 Million TWD | -19509.455% |
| SCI Pharmtech, Inc. | 1.59 Billion TWD | -884.289% |
| Formosa Laboratories, Inc. | 5.42 Billion TWD | -188.573% |
| PharmaEssentia Corporation | 3.32 Billion TWD | -371.459% |
| Bora Pharmaceuticals Co., LTD. | 13.28 Billion TWD | -17.851% |